A Study to Determine the Capacity of VAK694 When Combined With Allergen Immunotherapy to Bring About Specific Immune Tolerance

Inclusion criteria

• History of atopy, defined as a history of seasonal allergic rhinitis for at least 2 years (in relation to the grass pollen allergy season), and evidence of atopy, defined as a positive skin prick test (wheal difference allergen - negative control at least 3 mm) to grass pollen allergen at screening.
• Male or female subjects aged between 18 and 60 years (inclusive)
• Female subjects must be of non-childbearing potential
• Subjects must weigh at least 50 kg with a body mass index (BMI) within the range of 18 to 32 kg/m2 (inclusive)
• Informed consent

Exclusion criteria

• Treatment with intranasal corticosteroids within 28 days prior to the first dose.
• History of asthma with treatment with inhaled or systemic corticosteroids within 6 months of the first dose.
• History of COPD.
• Any exposure to human monoclonal or polyclonal antibodies.
• Any allergy immunotherapy within 3 years prior to screening.
• Any prior grass pollen allergy immunotherapy.
• FEV1 < 70% of predicted at screening or baseline.

Other protocol-defined inclusion/exclusion criteria may apply